Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol glycan anchor biosynthesis class W protein (PIGW) is an inositol acyltransferase enzyme localized in the endoplasmic reticulum, crucial for a key step in glycosylphosphatidylinositol (GPI) anchor biosynthesis[1][2][3][4]. PIGW catalyzes the transfer of a fatty acid from an acyl-CoA donor to the inositol ring of the GPI biosynthetic intermediate, glucosaminyl-phosphatidylinositol (GlcN-PI), enabling proper assembly and subsequent remodeling of GPI anchors, which tether many proteins to the cell surface[1][2][3][4]. Defects in PIGW lead to human diseases such as hyperphosphatasia with mental retardation syndrome type 5 (HPMRS5), a congenital disorder characterized by cognitive impairment, seizures, and biochemical abnormalities such as elevated alkaline phosphatase[1][3]. PIGW is essential for the cell surface expression of GPI-anchored proteins, and loss of this activity has broad cellular and clinical consequences[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class W protein (PIGW).